Genetic deletion of HK2 in a preclinical model of Kras driven lung cancer was sufficient to alter glucose metabolism and improve overall survival [12], suggesting that direct targeting of HK2 would be beneficial in PDAC. Here, HK2 is linked to lung carcinoma.